Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models

In this study we undertook a novel combination therapy using rAd-p53 in situ gene therapy and immunotherapy with immune checkpoint inhibitor (ICI) anti-PD-1 antibody for urogenital cancers. Three mouse syngeneic tumor cell lines, TRAMP-C2 (prostate cancer derived from C57BL/6 mice), MBT-2 (bladder c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunimura, Naoto, Kitagawa, Koichi, Sako, Ryota, Narikiyo, Keita, Tominaga, Shoko, Bautista, Diosdado S., Xu, Wei, Fujisawa, Masato, Shirakawa, Toshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562933/
https://www.ncbi.nlm.nih.gov/pubmed/33060772
http://dx.doi.org/10.1038/s41598-020-74660-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562933/
https://www.ncbi.nlm.nih.gov/pubmed/33060772
http://dx.doi.org/10.1038/s41598-020-74660-2

Ejemplares similares